Navigation Links
Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
Date:12/19/2007

ed through three intra-articular administrations of two milliliters each given at one-week intervals. Synvisc-One is delivered as three combined doses in just one single six milliliter administration. Competitive injection regimens call for up to five injections.

Safety and efficacy

Genzyme's regulatory filing for CE mark of Synvisc-One was based on final data from a prospective, randomized, double-blind, placebo-controlled study that involved 253 patients at 21 sites across Europe. In this study, a statistically significant improvement in pain from osteoarthritis of the knee was observed over 26 weeks when compared to pain relief for patients receiving placebo treatment.

Statistically significant differences in favor of Synvisc-One were also observed in several secondary outcome measures of efficacy, including patient and clinician global assessments. The safety profile of Synvisc-One was no different from that of placebo; also, there was no increased risk of post- injection adverse reactions in the patients receiving a second injection of Synvisc-One six months after the first injection.

Data from the study were presented earlier this year at the European League Against Rheumatism annual meeting in Barcelona, Spain and have been accepted for a podium presentation at the American Association of Orthopaedic Surgeons annual meeting in March, 2008.

"Synvisc-One provides long-term pain relief for patients without the systemic safety risks associated with traditional OA therapies such as NSAIDs and COX2 inhibitors," stated Xavier Chevalier M.D., Head of Rheumatology, Hopital Henri Mondor, Creteil France. "This is a unique opportunity for physicians to treat patients with a single injection viscosupplement that offers a very good risk-benefit profile."

About Synvisc

Synvisc is indicated for the treatment of pain due to osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonphar
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... (PRWEB) May 23, 2013 Patheon ... manufacturing services to the global pharmaceutical industry, will host ... Novel Approaches to Testing” on Tuesday, June 4, 2013 ... pharmaceutical manufacturers are required to comply with regulations for ... practices with limited scientific underpinning and little evaluation of ...
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... Z Trim Holdings, Inc. (OTC Markets: ZTHO), ... of industries, announced that Chef Erin Ryan ... year,s National Restaurant Association ("NRA") NRA Show, which was ... Research Chefs Association.  Chef Ryan spoke on the subject ... and the Ugly," joining four other prestigious panelists including: ...
(Date:5/23/2013)... During the conduct of research involving ... principles of good clinical practice (GCP) and human ... Lim, Fellow, Clinical Development at Novartis Pharmaceuticals, will ... the International Conference on Harmonization (ICH) Guideline for ... the conduction of clinical trials ,     Apply ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2
... Oct. 31, 2011 Azantis launches today AstaKrill™ , ... , a leading krill oil manufacturer, markets AstaKrill to resellers. ... that gives krill its distinct red color. The astaxanthin dosage ... other krill oils currently on the market. ...
... 31, 2011 Reportlinker.com announces that ... available in its catalogue: ... Analysis, Opportunity Assessment and Market Forecasts ... http://www.reportlinker.com/p0317992/Spinal-Implants---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices Spinal Implants ...
... , Spherix Incorporated (NASDAQ: ... in diabetes, metabolic syndrome and atherosclerosis, and providers of ... and pharmaceutical companies – today announced the closing of ... of its common stock together with warrants to purchase ...
Cached Biology Technology:AstaKrill™ the Best Krill Oil Boosts Astaxanthin 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 2Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 3
(Date:5/22/2013)... cell powered buses, including a team from Simon ... processes and bus membrane durability. , The team ... in the operating cycle of the bus on ... study, led by SFU graduate student Natalia MaCauley, ... Burnaby-based Ballard Power Systems and funded by Automotive ...
(Date:5/22/2013)... genetic engineering drastically reduces the time and effort ... workhorses of biotechnology, scientists are reporting. Published in ... method paves the way for more rapid development ... and other activities. , Keith Shearwin and colleagues ... the genetic material DNA into a bacterium,s genome ...
(Date:5/22/2013)... important new details on how climate change will affect ... in the Journal of Animal Ecology . This ... and informing policymakers of how species are likely to ... is a growing recognition among biologists that climate change ... that this is going to have very important consequences ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... more of the arteries in the lungs, including detecting ... may have little impact on the patient's outcome, a ... with suspected pulmonary embolism. About half of the patients ... had a single-detector CT examination. The radiology examinations came ...
... created the first active vaccine that can significantly delay and ... that is similar to mad cow disease. The new findings, ... a platform for the development of a vaccine to prevent ... particles called prions. , Although no cure for these diseases ...
... that allows immune cells known as neutrophils to protect ... at Washington University School of Medicine in St. Louis ... the development of an arthritis-like disorder by making the ... newly identified role for the gene, Foxo3a, may open ...
Cached Biology News:Newer imaging techniques may lead to over-treatment 2Active Vaccine Prevents Mice From Developing Prion Disease 2Active Vaccine Prevents Mice From Developing Prion Disease 3Disabling gene defuses rheumatoid arthritis in mice 2Disabling gene defuses rheumatoid arthritis in mice 3
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells stimulated with EGF Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Molecular Biological Resources offers bulk quantities of existing protein products. Please see the Chimerx divisions website for existing products and contact lloconne@molbiores.com for pricing....
Biology Products: